Bristol-Myers Squibb Co (NYSE:BMY) Shares Sold by Sigma Investment Counselors Inc.

Sigma Investment Counselors Inc. lessened its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 12.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 41,539 shares of the biopharmaceutical company’s stock after selling 5,891 shares during the period. Sigma Investment Counselors Inc.’s holdings in Bristol-Myers Squibb were worth $1,884,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Financial Gravity Wealth Inc. acquired a new stake in Bristol-Myers Squibb during the 1st quarter valued at $26,000. Capital Financial Planning LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $28,000. Private Ocean LLC acquired a new position in shares of Bristol-Myers Squibb in the first quarter worth $28,000. Well Done LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $30,000. Finally, Trust Department MB Financial Bank N A acquired a new position in shares of Bristol-Myers Squibb in the first quarter worth $32,000. Institutional investors own 77.61% of the company’s stock.

Bristol-Myers Squibb stock traded down $0.03 during mid-day trading on Friday, hitting $45.37. 20,309,114 shares of the company’s stock were exchanged, compared to its average volume of 11,805,174. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.79 and a current ratio of 1.93. The firm has a market capitalization of $74.02 billion, a PE ratio of 11.40, a P/E/G ratio of 2.02 and a beta of 0.71. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $63.69. The business has a 50 day moving average price of $45.93.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The firm had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. During the same period in the prior year, the business posted $1.01 earnings per share. The business’s quarterly revenue was up 10.0% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb Co will post 4.16 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 3.61%. The ex-dividend date is Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

In other news, Director Theodore R. Samuels II purchased 5,000 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was bought at an average cost of $47.29 per share, for a total transaction of $236,450.00. Following the completion of the acquisition, the director now directly owns 27,000 shares of the company’s stock, valued at $1,276,830. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Karen Murphy Santiago sold 3,065 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the sale, the insider now owns 3,066 shares of the company’s stock, valued at $145,818.96. The disclosure for this sale can be found here. 0.13% of the stock is owned by corporate insiders.

A number of equities analysts have recently weighed in on BMY shares. JPMorgan Chase & Co. upped their price target on shares of Masonite International from $66.00 to $71.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Argus downgraded shares of Clorox from a “buy” rating to a “hold” rating in a research note on Monday, May 20th. Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. UBS Group set a €110.00 ($127.91) price target on shares of Wacker Chemie and gave the stock a “buy” rating in a research note on Thursday, June 13th. Finally, BMO Capital Markets started coverage on shares of Yelp in a research note on Wednesday, April 17th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $56.22.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: What is a growth and income fund?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.